Overview

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

Status:
RECRUITING
Trial end date:
2026-09-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.
Phase:
PHASE3
Details
Lead Sponsor:
Guangdong Raynovent Biotech Co., Ltd